Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.84
OPK's Cash to Debt is ranked lower than
69% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. OPK: 2.84 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s 10-Year Cash to Debt Range
Min: 0.13  Med: 38.97 Max: No Debt
Current: 2.84
Equity to Asset 0.54
OPK's Equity to Asset is ranked lower than
65% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OPK: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s 10-Year Equity to Asset Range
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.54
-0.41
0.96
F-Score: 5
Z-Score: 5.51
M-Score: -3.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -174.31
OPK's Operating margin (%) is ranked lower than
60% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. OPK: -174.31 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44  Med: -408.51 Max: -39.08
Current: -174.31
-31624.44
-39.08
Net-margin (%) -246.86
OPK's Net-margin (%) is ranked lower than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. OPK: -246.86 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54  Med: -421.97 Max: -4.59
Current: -246.86
-44561.54
-4.59
ROE (%) -28.35
OPK's ROE (%) is ranked higher than
51% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. OPK: -28.35 )
Ranked among companies with meaningful ROE (%) only.
OPK' s 10-Year ROE (%) Range
Min: -3196.93  Med: -45.49 Max: -3.98
Current: -28.35
-3196.93
-3.98
ROA (%) -18.07
OPK's ROA (%) is ranked higher than
57% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. OPK: -18.07 )
Ranked among companies with meaningful ROA (%) only.
OPK' s 10-Year ROA (%) Range
Min: -1352.71  Med: -34.23 Max: -0.83
Current: -18.07
-1352.71
-0.83
ROC (Joel Greenblatt) (%) -1377.10
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. OPK: -1377.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93  Med: -1964.13 Max: -55.31
Current: -1377.1
-130662.93
-55.31
Revenue Growth (3Y)(%) 30.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
84% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OPK: 30.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -12.60 Max: 135.1
Current: 30.1
0
135.1
EBITDA Growth (3Y)(%) 69.40
OPK's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. OPK: 69.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.7  Med: 1.10 Max: 171.4
Current: 69.4
-75.7
171.4
EPS Growth (3Y)(%) 139.10
OPK's EPS Growth (3Y)(%) is ranked higher than
99% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. OPK: 139.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.4  Med: -1.60 Max: 152.4
Current: 139.1
-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

OPK Guru Trades in Q3 2014

Murray Stahl 138,935 sh (+10.33%)
George Soros 235,600 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 11,000 sh (-26.67%)
» More
Q4 2014

OPK Guru Trades in Q4 2014

Mario Gabelli 11,000 sh (unchged)
George Soros 235,600 sh (unchged)
Murray Stahl 125,752 sh (-9.49%)
» More
Q1 2015

OPK Guru Trades in Q1 2015

Ken Fisher 29,200 sh (New)
Jim Simons 1,253,398 sh (New)
Paul Tudor Jones 38,137 sh (New)
Mario Gabelli 11,000 sh (unchged)
George Soros 235,600 sh (unchged)
Murray Stahl 94,824 sh (-24.59%)
» More
Q2 2015

OPK Guru Trades in Q2 2015

Ken Fisher 29,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 476.19
OPK's Forward P/E is ranked lower than
96% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. OPK: 476.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 9.15
OPK's P/B is ranked lower than
73% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. OPK: 9.15 )
Ranked among companies with meaningful P/B only.
OPK' s 10-Year P/B Range
Min: 3.65  Med: 9.02 Max: 50.6
Current: 9.15
3.65
50.6
P/S 68.21
OPK's P/S is ranked lower than
82% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. OPK: 68.21 )
Ranked among companies with meaningful P/S only.
OPK' s 10-Year P/S Range
Min: 15.25  Med: 35.83 Max: 126.5
Current: 68.21
15.25
126.5
PFCF 45.47
OPK's PFCF is ranked lower than
51% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. OPK: 45.47 )
Ranked among companies with meaningful PFCF only.
OPK' s 10-Year PFCF Range
Min: 38.97  Med: 43.17 Max: 49.39
Current: 45.47
38.97
49.39
POCF 44.24
OPK's POCF is ranked lower than
58% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. OPK: 44.24 )
Ranked among companies with meaningful POCF only.
OPK' s 10-Year POCF Range
Min: 37.92  Med: 42.00 Max: 48.05
Current: 44.24
37.92
48.05
Current Ratio 2.16
OPK's Current Ratio is ranked lower than
72% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. OPK: 2.16 )
Ranked among companies with meaningful Current Ratio only.
OPK' s 10-Year Current Ratio Range
Min: 0.88  Med: 6.40 Max: 415
Current: 2.16
0.88
415
Quick Ratio 2.05
OPK's Quick Ratio is ranked lower than
69% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. OPK: 2.05 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s 10-Year Quick Ratio Range
Min: 0.48  Med: 6.40 Max: 415
Current: 2.05
0.48
415
Days Inventory 141.09
OPK's Days Inventory is ranked lower than
58% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. OPK: 141.09 )
Ranked among companies with meaningful Days Inventory only.
OPK' s 10-Year Days Inventory Range
Min: 131.84  Med: 255.62 Max: 500.07
Current: 141.09
131.84
500.07
Days Sales Outstanding 70.33
OPK's Days Sales Outstanding is ranked lower than
58% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. OPK: 70.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s 10-Year Days Sales Outstanding Range
Min: 38.86  Med: 163.92 Max: 727.85
Current: 70.33
38.86
727.85

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 11.06
OPK's Price/Projected FCF is ranked lower than
67% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. OPK: 11.06 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s 10-Year Price/Projected FCF Range
Min: 7.16  Med: 17.12 Max: 236.67
Current: 11.06
7.16
236.67
Price/Median PS Value 1.91
OPK's Price/Median PS Value is ranked lower than
74% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. OPK: 1.91 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 1.28 Max: 9.58
Current: 1.91
0.31
9.58
Earnings Yield (Greenblatt) (%) -3.20
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. OPK: -3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.41  Med: 0.00 Max: 0
Current: -3.2
-3.41
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Mexico, OPK.Israel,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
my portfolio Jul 24 2015 
my portfolio Jul 24 2015 
Weekly CEO Buys Highlight: CLMS, OPK, ROVI, LPG, GAM Jul 13 2015 
Weekly CEO Buys Highlight: GPP, CLMS, ADC, SNR, OPK Jul 06 2015 
mio Jun 09 2015 
mio Jun 09 2015 
mio Jun 09 2015 
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Weekly CEO Buys Highlight: OPK, CLMS, GFF, TCB, SFNC May 12 2015 
CNN To Use Drone Aviation Holding's Products For FAA Research May 08 2015 

More From Other Websites
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 Jul 30 2015
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 Jul 30 2015
FDA Accepts OPKO's New Drug Application for Rayaldee™ Jul 28 2015
FDA Accepts OPKO’s New Drug Application for Rayaldee™ Jul 28 2015
Opko Health: Why Recent Weakness Represents A Golden Buying Opportunity Jul 24 2015
OPKO's Prostate Cancer Hit Jul 23 2015
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources Jul 10 2015
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient... Jul 10 2015
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient... Jul 10 2015
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources Jul 10 2015
FuelCell Energy, Windstream And Others Insiders Have Been Buying Jul 07 2015
4 Stocks Rising on Unusual Volume Jul 07 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 05 2015
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Jul 02 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
3 Reasons Why Opko Health's Stock Could Soar Jul 01 2015
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts Jul 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK